Pyrovalerone

Pyrovalerone

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	AU: S4 (Prescription only) CA: Schedule IV DE: Anlage II (Prohibited) UK: Class C US: Schedule V
Identifiers
IUPAC name (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)pentan-1-one
CAS Number	3563-49-3 N
PubChem CID	14373
ChemSpider	13733 Y
UNII	VOU69C02JP
ChEMBL	CHEMBL201960 Y
ECHA InfoCard	100.230.426
Chemical and physical data
Formula	C16H23NO
Molar mass	245.36 g/mol
3D model (Jmol)	Interactive image
Chirality	Racemic mixture
SMILES O=C(C(CCC)N1CCCC1)C2=CC=C(C)C=C2
InChI InChI=1S/C16H23NO/c1-3-6-15(17-11-4-5-12-17)16(18)14-9-7-13(2)8-10-14/h7-10,15H,3-6,11-12H2,1-2H3 Y Key:SWUVZKWCOBGPTH-UHFFFAOYSA-N Y
NY (what is this?)

Pyrovalerone (Centroton, 4-Methyl-β-keto-prolintane, Thymergix, O-2371) is a psychoactive drug with stimulant effects via acting as a norepinephrine-dopamine reuptake inhibitor (NDRI), and is used for the clinical treatment of chronic fatigue or lethargy and as an anorectic or appetite suppressant for weight loss purposes. It was developed in the late 1960s and has since been used in France and several other European countries, and although pyrovalerone is still occasionally prescribed, it is used infrequently due to problems with abuse and dependence. It is closely related on a structural level to a number of other stimulants, such as MDPV and prolintane (Promotil, Katovit).

Side effects of pyrovalerone include anorexia or loss of appetite, anxiety, fragmented sleep or insomnia, and trembling, shaking, or muscle tremors. Withdrawal following abuse upon discontinuation often results in depression.